Atlas chapter 11 · Oncology (adjunctive)

Huaier

Vanderbylia robiniophila (historical clinical taxa: Trametes robiniophila; Perenniporia robiniophila)

E4++ — Supports the tested propositionR2 — substantial corroborative human evidence exists, but the grade-determining proposition remains dependent on one landmark randomized programme and lacks comparable independent randomized replication

Proposition / claim: Standardized Huaier granules reduced postoperative recurrence risk after curative resection for hepatocellular carcinoma (HCC) in the landmark randomized clinical programme.
Evidence owner: Standardized Huaier granules as used in the audited clinical programme. The biological source is Huaier / Vanderbylia robiniophila, but the grade-owning clinical evidence belongs to the standardized granule intervention. E4+ does not transfer automatically to arbitrary Huaier supplements, generic fungal extracts, powders or materially different preparations carrying the Huaier name.
Dominant uncertainty: Independent contemporary randomized replication — whether an independent contemporary randomized programme will reproduce the postoperative-HCC recurrence result. The dominant uncertainty is replication, not basic biological plausibility, taxonomy, the size of the landmark trial, or the existence of mechanistic literature.

Organism: Vanderbylia robiniophila
Tested intervention: Standardized Huaier granules
Evidence target: Standardized preparation
Intervention description: The standardized Huaier granule preparation used in the audited clinical programme. The evidence belongs to this standardized granule preparation; Huaier-labelled products of other composition, processing or dosage are not assumed equivalent.
Population: Patients who had undergone curative resection for hepatocellular carcinoma in the landmark multicentre randomized clinical programme: 1,044 randomized patients across 39 centres, 2:1 randomization, maximum 96 weeks.
Comparator: No further treatment / no-Huaier control as represented in the landmark trial. The programme used a no-Huaier control rather than a matched placebo.
Outcome: Primary grade-owning outcome: recurrence-free survival (RFS). Mean RFS 75.5 weeks versus 68.5 weeks; hazard ratio 0.67 (95% CI 0.55–0.81); reported RFS rates 62.39% versus 49.05%. Secondary outcomes recorded include overall survival (95.19% versus 91.46%) and extrahepatic recurrence (8.60% versus 13.61%).
Evidence maturity (E): E4+
Direction: + — Supports the tested proposition
Historical flag (H): Not specified at dossier level
Replication (R): R2 — substantial corroborative human evidence exists, but the grade-determining proposition remains dependent on one landmark randomized programme and lacks comparable independent randomized replication
Claim Gap (CG): CG0 — A large randomized multicentre trial found improved recurrence-free survival with standardized Huaier granules after curative HCC resection. CG1 — Huaier may reduce postoperative HCC recurrence. CG1–2 — Huaier may help reduce the risk of liver cancer returning after surgery. CG3 — Huaier has clinically proven anticancer activity. CG4 — Huaier fights cancer. Claim ceiling: CG1 for postoperative-HCC wording. As the wording expands, surgery, cancer type, recurrence endpoint, preparation and replication status progressively disappear.
Evidence Transfer Vector: I / R / P / C — for the transferred claim "Any Huaier supplement prevents liver-cancer recurrence." I — Intervention: standardized clinical granules → arbitrary supplement. R — Replication: one landmark randomized programme → established universal effect. P / C — Population / clinical context: postoperative HCC patients → broader populations and clinical contexts.
Taxonomic Transfer Confidence: HIGH — the historical-to-current nomenclatural bridge (Trametes robiniophila / Perenniporia robiniophila → Vanderbylia robiniophila) is comparatively manageable. High taxonomic transfer confidence does not imply high intervention transfer confidence.
Intervention Transfer Confidence: LOW-MODERATE unless equivalence is demonstrated
Safety: S2
Conservation: C0/C+
Resolution zone: RZ-3
Next best experiment: Run an independent multicentre postoperative-HCC trial using the same well-characterized Huaier preparation, or one with demonstrated equivalence, in a current surgical and surveillance context. Prespecify recurrence-free survival as the primary endpoint. Use adequate statistical power, independent investigators and analysis where possible, full preregistration, and archived intervention batches. The purpose is genuine independent replication capable of confirming or contradicting the landmark result — not a further small exploratory or mechanistic study.
Primary references: Chen Q, Shu C, Laurence AD, Chen Y, Peng B-G, Zhen Z-J, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial. Gut. 2018;67(11):2006-2016. DOI: 10.1136/gutjnl-2018-315983. PMID: 29802174. — GRADE-OWNING. The landmark phase IV multicentre randomized programme that owns the E4+ grade and the dossier proposition. Intervention: standardized Huaier granule preparation (aqueous extract of Trametes robiniophila Murr) as supplied in the trial; not any Huaier-labelled supplement. Population: 1,044 patients randomized 2:1 across 39 centres after curative resection for hepatocellular carcinoma, treated for a maximum of 96 weeks. Comparator: no further treatment (no-Huaier control), NOT a matched placebo. Endpoint: recurrence-free survival — mean RFS 75.5 vs 68.5 weeks; HR 0.67 (95% CI 0.55-0.81); RFS rate 62.39% vs 49.05%; overall survival 95.19% vs 91.46%; extrahepatic recurrence 8.60% vs 13.61%. Methodological limitation: open-label, unblinded, no placebo control; conducted within one coordinated national programme. Replication: contributes ONE randomized programme; the 39 centres are sites of a single trial and do not constitute independent replications. Intervention identity: fixes evidence ownership to the standardized granule preparation actually administered.
Luo S, Hu H. Huaier granule prolongs overall survival after curative resection of hepatocarcinoma carcinoma: a propensity score analysis. Journal of Ethnopharmacology. 2023;301:115774. DOI: 10.1016/j.jep.2022.115774. PMID: 36206867. — CORROBORATIVE, OBSERVATIONAL. Retrospective propensity-score-matched cohort of post-resection HCC patients receiving Huaier granules versus not. Non-randomized: allocation is by clinical practice, so residual confounding by indication, adherence and health-seeking behaviour cannot be excluded. Supports directional consistency with the landmark trial but does NOT constitute independent randomized replication and does not raise R2.
Xie K, Ma M, Xu F, et al. Long-term oral administration of Huaier granules improves survival outcomes in hepatocellular carcinoma patients within Milan criteria following microwave ablation: a propensity score matching and stabilized inverse probability weighting analysis. Frontiers in Pharmacology. 2024;15:1336347. DOI: 10.3389/fphar.2024.1336347. PMID: 38774215. PMCID: PMC11106438. — CORROBORATIVE, OBSERVATIONAL, DIFFERENT CLINICAL CONTEXT. Population is post-microwave-ablation HCC within Milan criteria, not post-curative-resection; the clinical context therefore differs from the grade-owning proposition. Non-randomized design with propensity-score matching and stabilized IPW. Relevant to transportability discussion only; not independent randomized replication of the postoperative-resection recurrence proposition.
Zhou T, Zhang Y, Lu Y, Sun Z, et al. The efficacy of combined use of Huaier granules in the treatment of primary liver cancer: an updated systematic review and meta-analysis. Pharmaceuticals (Basel). 2025;18(6):884. DOI: 10.3390/ph18060884. PMID: 40573279. PMCID: PMC12196447. — SECONDARY SYNTHESIS (REVIEW / META-ANALYSIS). Pools heterogeneous studies of Huaier granules combined with conventional treatment for primary liver cancer. A meta-analysis is not itself new primary evidence: it re-uses the landmark trial and lower-quality, largely non-blinded or non-randomized studies, and inherits their limitations. Useful for situating the literature; does not add an independent randomized replication and does not change E4+ or R2.
Ji H, Ma W, Zheng A, Tang D, et al. The role and molecular mechanism of Trametes robiniophila Murr (Huaier) in tumor therapy. Journal of Ethnopharmacology. 2024;334:118578. DOI: 10.1016/j.jep.2024.118578. PMID: 39004194. — MECHANISTIC REVIEW. Summarizes preclinical and molecular work on Huaier extracts and fractions across tumour models. Preparations studied in the mechanistic literature are heterogeneous and frequently not the standardized clinical granule, so this evidence supports biological plausibility only. Plausibility is not provenance: it contributes no clinical grade, no replication, and cannot transfer clinical evidence to other Huaier-derived materials.
Source chapter: Chapter 11, The Fungal Evidence Atlas